SCHEMBL3760247

SCHEMBL3760247

Cc1ccc2nc(C)cc(O)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 3/20 0.50
GFER P55789 2/20 0.50
CYP1A2 P05177 4/20 0.48
HTT P42858 2/20 0.47
ELANE P08246 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAD52 P43351 1/20 0.44
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
MITF O75030 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KCNH2 Q12809 1/20 0.43
GAA P10253 2/20 0.42
JAK2 O60674 1/20 0.42
PAX8 Q06710 1/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11401003 0.84 ELANE (0.49) LMNAL3MBTL1KDM4EGFERCYP1A2
SCHEMBL6593684 0.84 CYP1A2 (0.50) LMNAL3MBTL1KDM4EGFERCYP1A2
SCHEMBL29923741 0.81 ALDH1A1 (0.55) KDM4ECYP1A2HTTSMN1; SMN2MAPT
SCHEMBL4748554 0.81 POLB (0.53) LMNAL3MBTL1KDM4EHTTSMN1; SMN2
SCHEMBL3390039 0.81 NQO2 (0.53) LMNAL3MBTL1KDM4ECYP1A2SMN1; SMN2
SCHEMBL3906125 0.81 GAA (0.47) LMNAKDM4ECYP1A2ALDH1A1GAA
SCHEMBL4966064 0.81 ALDH1A1 (0.55) KDM4ECYP1A2HTTSMN1; SMN2MAPT
SCHEMBL3642253 0.81 LMNA (0.41) LMNAL3MBTL1KDM4EGFERCYP1A2
SCHEMBL8134109 0.81 LMNA (0.53) LMNAL3MBTL1KDM4ECYP1A2ELANE
SCHEMBL11399020 0.81 BACE1 (0.52) LMNAKDM4ECYP1A2HTTELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0124752-B1 MIXTURES OF SUBSTANCES WITH GROWTH AND OUTPUT ACCELERATING EFFECT AS WELL AS FEED AND WATERING LIQUIDS WHICH CONTAIN LOW AMOUNTS OF THESE MIXTURES BASF Aktiengesellschaft (DE) 1986-07-16 EP claimed
EP-0065192-B1 GROWTH-PROMOTING FODDER OR DRINKING LIQUID BASF Aktiengesellschaft (DE) 1984-02-01 EP claimed
US-20100305326-A1 Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage MARQUETTE UNIVERSITY (US) 2010-12-02 US disclosed
US-20100305326-A1 Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage MARQUETTE UNIVERSITY (US) 2010-12-02 US disclosed
US-20100305326-A1 Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage MARQUETTE UNIVERSITY (US) 2010-12-02 US disclosed
EP-0113432-B1 CHLOROMETHYL QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE ALKALOIDA VEGYéSZETI GYáR (HU) 1993-03-17 EP disclosed
US-4632983-A Pyridone dyes containing a oxydiazone substituent BASF AKTIENGESELLSCHAFT (DE) 1986-12-30 US disclosed
US-4599345-A BACTERICIDES, FUNGICIDES ANTIINFLAMMATORY ALKALOIDE VEGYESZETI GYAR (HU) 1986-07-08 US disclosed
EP-0113432-A1 Chloromethyl quinoline derivatives, process for their preparation and their use ALKALOIDA VEGYéSZETI GYáR (HU) 1984-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305326-A1 Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage CYFIP2, RPS27A, FRS2 LMNA 2178/4885L3MBTL1 3503/4885KDM4E 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.